5/8
06:40 am
clrb
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
Medium
Report
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
5/7
06:40 am
clrb
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024
Low
Report
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024
3/29
08:16 am
clrb
Cellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven? [Yahoo! Finance]
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven? [Yahoo! Finance]
3/28
11:03 pm
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) was upgraded by analysts at StockNews.com to a "sell" rating.
3/28
10:46 am
clrb
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/28
08:06 am
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $12.00 price target on the stock, up previously from $11.00.
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $12.00 price target on the stock, up previously from $11.00.
3/27
06:43 am
clrb
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update [Yahoo! Finance]
Medium
Report
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update [Yahoo! Finance]
3/27
06:40 am
clrb
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
Medium
Report
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
3/20
06:49 am
clrb
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 [Yahoo! Finance]
Low
Report
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 [Yahoo! Finance]
3/20
06:40 am
clrb
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
Low
Report
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
3/14
08:52 am
clrb
Cellectar Biosciences to Present at the 36th Annual Roth Conference
Medium
Report
Cellectar Biosciences to Present at the 36th Annual Roth Conference
3/4
01:11 pm
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $20.00 price target on the stock.
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $20.00 price target on the stock.
3/4
06:51 am
clrb
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer [Yahoo! Finance]
Low
Report
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer [Yahoo! Finance]
3/4
06:40 am
clrb
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
Low
Report
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
2/12
01:42 am
clrb
Cellectar Biosciences: A Shoestring Opportunity You're About To Miss [Seeking Alpha]
Low
Report
Cellectar Biosciences: A Shoestring Opportunity You're About To Miss [Seeking Alpha]